Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma

Acta Medica Okayama

Volumn 63, Issue 6, 2009, Pages 299-304

  Fujikawa, Tatsuya ^a   Shiraha, Hidenori ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cell proliferation; Des carboxy prothrombin; Hepatocellular carcinoma; Signaling pathway

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; GLUTAMYL CARBOXYLASE; LIGASE; PROTEIN PRECURSOR; PROTHROMBIN; SIGNAL PEPTIDE; TUMOR MARKER;

CELL MOTION; CELL PROLIFERATION; ENDOTHELIUM CELL; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BIOLOGICAL MARKERS; CARBON-CARBON LIGASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 74349126580     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 132: 2557-2576.
2. Addeo R, Caraglia M and Del Prete S: Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs (2009) 18: 373-378.
3. Omata M: Modalities of prevention of recurrence after tumor ablation/resection of HCC. J Gastroenterol Hepatol (2004) 19: S270.
4. Hussain K and El-Serag HB: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol (2009)55: 123-138.
5. Nakakura EK and Choti MA: Management of hepatocellular carcinoma. Oncology (Williston Park) (2000) 14: 1085-1098; discussion 1098-1102.
6. Izumi R, Shimizu K, Kiriyama M, Hashimoto T, Urade M, Yagi M, Mizukami Y, Nonomura A and Miyazaki I: Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol (1992) 49: 151-155.
7. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y and Nagataki S. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med (1993) 328: 1802-1806.
8. Ramsey WH and Wu GY: Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis (1995) 13: 81-91.
9. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T and Kasukawa R: Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol (2000) 95: 1036-1040.
10. Sherman M: Alphafetoprotein:an obituary. J Hepatol (2001) 34: 603-605.
11. Ward J and Robinson PJ: How to detect hepatocellular carcinoma in cirrhosis. Eur Radiol (2002) 12: 2258-2272.
12. Uehara S, Gotoh K, Handa H, Honjo K and Hirayama A: Process of carboxylation of glutamic acid residues in the gla domain of human des-gamma-carboxyprothrombin. Clin Chim Acta (1999) 289: 33-44.
13. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med (1984) 310: 1427-1431.
14. Fujiyama S, Morishita T, Hashiguchi O and Sato T: Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer (1988) 61: 1621-1628.
15. Nakao A, Taniguchi K, Inoue S, Harada A, Nonami T, Watanabe K and Takagi H: Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepato cellular carcinoma. Semin Surg Oncol (1996) 12: 160-163.
16. Giannelli G and Antonaci S: New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis (2006) 38: 854-859.
17. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M and Nakano M: Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer (2000) 88: 544-549.
18. Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K and Aoyagi Y: Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma. Hepatogastroenterology (1998) 45: 1737-1741.
19. Okuda H, Nakanishi T, TakatsuK, Saito A, Hayashi N, Yamamoto M, Takasaki K and Nakano M: Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol (2001) 16: 1290-1296.
20. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, Yoshida H and Omata M: Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer (2000) 88: 1557-1564.
21. Inoue S, Nakao A, Harada A, Nonami T and Takagi H: Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carci noma. Am J Gastroenterol (1994) 89: 2222-2226.
22. Suehiro T, Matsumata T, Itasaka H, Taketomi A, Yamamoto K and Sugimachi K: Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery (1995) 117: 682-691.
23. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, Makuuchi M and Kawasaki S: Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg (1999) 86: 1032-1038.
24. Nanashima A, Morino S, Yamaguchi H, Tanaka K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T and Nakagoe T: Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol (2003) 29: 735-742.
25. Shimada M, Yonemura Y, Ijichi H, Harada N, Shiotani S, Ninomiya M, Terashi T, Yoshizumi T, Soejima Y and Maehara Y: Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc (2005) 37: 1177-1179.
26. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T and Maehara Y: Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation (2009) 87: 531-537.
27. Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Nagai T, Minami Y and Ueshima K: PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology (2008) 75 Suppl 1: 91-98.
28. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M and Matsunaga T: Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol (2008) 49: 223-232.
29. Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y and Kumada H: High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer (2009) 115: 571-580.
30. Maeda S, Fujiyama S, Tanaka M, Ashihara H, Hirata R and Tomita K: Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res (2002) 23: 202-210.
31. Nakao A, Suzuki Y, Isshiki K, KimuraY, Takeda S, Kishimoto W, Nonami T, Harada A and Takagi H: Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J astroenterol (1991) 86: 62-66.
32. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R and Tomita K: Tumor markers in early diagnosis, follow-up and man agement of patients with hepatocellular carcinoma. Oncology (2002) 62 Suppl 1: 57-63.
33. Shimada M, Takenaka K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, Shirabe K and Sugimachi K: Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer (1996) 78: 2094-2100.
34. Miyaaki H, Nakashima O, Kurogi M, Eguchi K and Kojiro M: Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol (2007) 42: 962-968.
35. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S and Omata M: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer (2001) 91: 561-569.
36. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M and Nakatani T: Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol (2006) 41: 1214-1219.
37. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y and Washizu J: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol (2006) 4: 111-117.
38. Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, Ando E, Tanaka M and Sata M: Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-ll. Liver Int (2006) 26: 789-795.
39. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, LeeJH, Kim HY and Jang MK: Prognostic Values of alpha-fetoprotein and Protein Induced by Vitamin K Absence or Antagonit-ll in Hepatitis B Virus-related Hepatocellular Carcinoma: A Prospective Study. J Clin Gastroenterol (2009) 43: 482-488.
40. Wu SM, Cheung WF, Frazier D and Stafford DW: Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science (1991) 254: 1634-1636.
41. Wu SM, Morris DP and Stafford DW: Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci USA (1991) 88: 2236-2240.
42. Liu Y, Nelson AN and Lipsky JJ: Vitamin K-dependent carboxylase: mRNA distribution and effects of vitamin K-deficiency and warfarin treatment. Biochem Biophys Res Commun (1996) 224: 549-554.
43. Romero EE, Deo R, Velazquez-Estades LJ and Roth DA: Cloning, structural organization, and transcriptional activity of the rat vitamin K-dependent gamma-glutamyl carboxylase gene. Biochem Biophys Res Commun (1998) 248: 783-788.
44. Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B and Solera J: Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood (1997)89: 4058-4062.
45. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie JW, Bezeaud A, Stafford DW and Guillin MC: Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer (1994) 74: 1533-1541.
46. Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW and Solera J: A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood (1998) 92: 4554-4559.
47. Rost S, Fregin A, Koch D, Compes M, Muller CR and Oldenburg J: Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol (2004) 126: 546-549.
48. Spronk HM, Farah RA, Buchanan GR, Vermeer C and Soute BA: Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood (2000) 96: 3650-3652.
49. Tagawa M, Omata M and Ohto M: Nucleotide sequence of prothrombin gene in abnormal prothrombin-producing hepatocellular carcinoma cell lines. Cancer (1992) 69: 643-647.
50. Ueda N, Shiraha H, Fujikawa T, Takaoka N, Nakanishi Y, Suzuki M, Matsuo N, Tanaka S, Nishina S, Uemura M, Takaki A, Shiratori Y and Yamamoto K: Exon 2 deletion splice variant of g-glutamyl carboxylase causes des-g-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol (2008) 2: 241-249.
51. Li ZQ, He FY, Stehle CJ, Wang Z, Kar S, Finn FM and Carr Bl: Vitamin K uptake in hepatocytes and hepatoma cells. Life Sci (2002) 70: 2085-2100.
52. Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T and Omata M: Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology (2004) 40: 243-251.
53. Price PA and Williamson MK: Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate. Protein Sci (1993) 2: 1987-1988.
54. Pudota BN, Hommema EL, Hallgren KW, McNally BA, Lee S and Berkner KL: Identification of sequences within the gamma-carboxylase that represent a novel contact site with vitamin K-dependent proteins and that are required for activity. J Biol Chem (2001) 276: 46878-46886.
55. Furukawa M, Nakanishi T, Okuda H, Ishida S and Obata H: Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer (1992) 69: 31-38.
56. Okuda H, Obata H, Nakanishi T, Furukawa R and Hashimoto E: Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol (1987) 4: 357-363.
57. Sakon M, Monden M, Gotoh M, Kanai T, Umeshita K, Nakano Y, Mori T, Sakurai M and Wakasa K: Relationship between patho logic prognostic factors and abnormal levels of des-gamma-carboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg(1992) 163: 251-256.
58. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A and Shiratori Y: Des-gammacarboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem (2005) 280: 6409-6415.
59. Tamano M, Sugaya H, Oguma M, lijima M, Yoneda M, Murohisa T, Kojima K, Kuniyoshi T, Majima Y, Hashimoto T and Terano A: Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res (2002) 22: 261-269.
60. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K and Shiratori Y: Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem (2007)282: 8741-8748.